Journal article

Differences between first episode schizophrenia and schizoaffective disorder

SM Cotton, M Lambert, BG Schimmelmann, A Mackinnon, JFM Gleeson, M Berk, L Hides, AM Chanen, J Scott, D Schoettle, PD McGorry, P Conus

Schizophrenia Research | ELSEVIER SCIENCE BV | Published : 2013

Grants

Funding Acknowledgements

The First Episode Outcome Study (FEPOS) was supported by a grant to Prof. Martin Lambert from Eli Lilly Company Australia, and a grant to Prof. Philippe Conus from the Leenaards Foundation, Switzerland. Eli Lilly Australia funded the assessment of files on a subgroup of this cohort treated with olanzapine and risperidone.Prof. Lambert, Prof. Conus, Prof. Schimmelmann, and Prof. McGorry have served on the speakers' board of Eli Lily. Prof. Berk has served on advisory boards and received funds and/or honoraria from Astra Zeneca, Eli Lilly, Janssen Cilag, Lundbeck, Servier, Glaxo Smith Kline, Organon, Novartis, Pfizer, Bristol Myers Squibb, Sanofi Synthelabo and Solvay.The First Episode Outcome Study (FEPOS) was supported by a grant to Prof. Martin Lambert from Eli Lilly Company Australia, and a grant to Prof. Philippe Conus from the Leenaards Foundation, Switzerland. Eli Lilly Australia funded the assessment of files on a subgroup of this cohort treated with olanzapine and risperidone.